Advertisement

Interferon-Based Therapy for Hepatitis C Virus Infections

  • Ming-Lung Yu
  • Wan-Long Chuang

Keywords

Chronic Hepatitis Sustained Virological Response Rate Rapid Virological Response High Sustained Virological Response Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bodenheimer, H.C., Jr., Lindsay, K.L., Davis, G.L., Lewis, J.H., Thung, S.N., Seeff, L.B. (1997). Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology, 26: 473–477.PubMedGoogle Scholar
  2. Bressler, B.L., Guindi, M., Tomlinson, G., Heathcote, J. (2003). High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology, 38: 639–644.PubMedGoogle Scholar
  3. Bruchfeld, A., Lindahl, K., Schvarcz, R., Stahle, L. (2002). Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Therapeutic Drug Monitoring, 24: 701–708.PubMedGoogle Scholar
  4. Bukh, J., Miller, R.H., Purcell, R.H. (1995). Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Seminars in Liver Disease, 15: 41–63.PubMedGoogle Scholar
  5. Carithers, R.L., Jr., Emerson, S.S. (1997). Therapy of hepatitis C: meta-analysis of interferon alpha-2b trials. Hepatology, 26: 83S–88S.PubMedGoogle Scholar
  6. Carrat, F., Bani-Sadr, F., Pol, S., Rosenthal, E., Lunel-Fabiani, F., Benzekri, A., Morand, P., Goujard, C., Pialoux, G., Piroth, L., Salmon-Ceron, D., Degott, C., Cacoub, P., Perronne, C. (2004). Pegylated interferon alpha-2b vs standard interferon alpha-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. Journal of the American Medical Association, 292: 2839–2848.PubMedGoogle Scholar
  7. Chen, L., Borozan, I., Feld, J., Sun, J., Tannis, L.L., Coltescu, C., Heathcote, J., Edwards, A.M., McGilvray, I.D. (2005). Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology, 128: 1437–1444.PubMedGoogle Scholar
  8. Chuang, W.L., Dai, C.Y., Chen, S.C., Lee, L.P., Lin, Z.Y., Hsieh, M.Y., Wang, L.Y., Yu, M.L., Chang, W.Y. (2004). Randomized trial of three different regimens for 24 weeks for re-treatment of chronic hepatitis C patients who failed to respond to interferon-alpha monotherapy in Taiwan. Liver International, 24: 595–602.PubMedGoogle Scholar
  9. Chuang, W.L., Dai, C.Y., Chang, W.Y., Lee, L.P., Lin, Z.Y., Chen, S.C., Hsieh, M.Y., Wang, L.Y., Yu, M.L. (2005). Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy. Antiviral Therapy, 10: 125–133.PubMedGoogle Scholar
  10. Chung, R.T., Andersen, J., Volberding, P., Robbins, G.K., Liu, T., Sherman, K.E., Peters, M.G., Koziel, M.J., Bhan, A.K., Alston, B., Colquhoun, D., Nevin, T., Harb, G., van der Horst, C. (2004). Peginterferon alpha-2a plus ribavirin versus interferon alpha-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. New England Journal of Medicine, 351: 451–459.PubMedGoogle Scholar
  11. Cramp, M.E., Rossol, S., Chokshi, S., Carucci, P., Williams, R., Naoumov, N.V. (2000). Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology, 118: 346–355.PubMedGoogle Scholar
  12. Crotty, S., Maag, D., Arnold, J.J., Zhong, W., Lau, J.Y., Hong, Z., Andino, R., Cameron, C.E. (2000). The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nature Medicine, 6: 1375–1379.PubMedGoogle Scholar
  13. D’Souza, R., Sabin, C.A., Foster, G.R. (2005). Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. American Journal of Gastroenterology, 100: 1509–1515.PubMedGoogle Scholar
  14. Dai, C.Y., Chuang, W.L., Chang, W.Y., Chen, S.C., Lee, L.P., Hsieh, M.Y., Hou, N.J., Lin, Z.Y., Hsieh, M.Y., Wang, L.Y., Yu, M.L. (2005). Polymorphisms in the interferon-gamma gene at position +874 in patients with chronic hepatitis C treated with high-dose interferon-alpha and ribavirin. Antiviral Research, 67: 93–97.PubMedGoogle Scholar
  15. Dai, C.Y., Chuang, W.L., Chang, W.Y., Chen, S.C., Lee, L.P., Hsieh, M.Y., Hou, N.J., Lin, Z.Y., Huang, J.F., Hsieh, M.Y., Wang, L.Y., Yu, M.L. (2006). Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection. Journal of Infectious Disease, 193: 98–101.Google Scholar
  16. Dalgard, O., Bjoro, K., Hellum, K.B., Myrvang, B., Ritland, S., Skaug, K., Raknerud, N., Bell, H. (2004). Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology, 40: 1260–1265.PubMedGoogle Scholar
  17. Davis, G.L., Balart, L.A., Schiff, E.R., Lindsay, K., Bodenheimer, H.C., Jr., Perrillo, R.P., Carey, W., Jacobson, I.M., Payne, J., Dienstag, J.L., et al. (1989). Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. New England Journal of Medicine, 321: 1501–1506.PubMedGoogle Scholar
  18. Davis, G.L., Lau, J.Y. (1995). Choice of appropriate end points of response to interferon therapy in chronic hepatitis C virus infection. Journal of Hepatology, 22: 110–114.PubMedGoogle Scholar
  19. Davis, G. L. (2002). Monitoring of viral levels during therapy of hepatitis C. Hepatology, 36: S145–151.PubMedGoogle Scholar
  20. Davis, G.L., Wong, J.B., McHutchison, J.G., Manns, M.P., Harvey, J., Albrecht, J. (2003). Early virologic response to treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C. Hepatology, 38: 645–652.PubMedGoogle Scholar
  21. Di Bisceglie A.M., Hoofnagle, J.H. (2002). Optimal therapy of hepatitis C. Hepatology, 36: S121–127.Google Scholar
  22. Di Bisceglie, A.M., Martin, P., Kassianides, C., Lisker-Melman, M., Murray, L., Waggoner, J., Goodman, Z., Banks, S.M., Hoofnagle, J.H. (1989). Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. New England Journal of Medicine, 321: 1506–1510.PubMedGoogle Scholar
  23. Dixit, N.M., Layden-Almer, J.E., Layden, T.J., Perelson, A.S. (2004). Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature, 432: 922–924.PubMedGoogle Scholar
  24. EASL International Consensus Conference on Hepatitis C. Paris, 26-27 February 1999. Consensus statement. Journal of Hepatology, 31 Suppl. 1: 3–8.Google Scholar
  25. el-Sayed, H.F., Abaza, S.M., Mehanna, S., Winch, P.J. (1997). The prevalence of hepatitis B and C infections among immigrants to a newly reclaimed area endemic for Schistosoma mansoni in Sinai, Egypt. Acta Tropica, 68: 229–237.PubMedGoogle Scholar
  26. Enomoto, N., Sakuma, I., Asahina, Y., Kurosaki, M., Murakami, T., Yamamoto, C., Ogura, Y., Izumi, N., Marumo, F., Sato, C. (1996). Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. New England Journal of Medicine, 334: 77–81.PubMedGoogle Scholar
  27. Feld, J.J., Hoofnagle, J.H. (2005). Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature, 436: 967–972.PubMedGoogle Scholar
  28. Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinos, G., Goncales, F.L., Jr., Haussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J., Yu, J. (2002). Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine, 347: 975–982.PubMedGoogle Scholar
  29. Hadziyannis, S.J., Sette, H., Jr., Morgan, T.R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H., Jr., Bernstein, D., Rizzetto, M., Zeuzem, S., Pockros, P.J., Lin, A., Ackrill, A.M. (2004). Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Annals of Internal Medicine, 140: 346–355.PubMedGoogle Scholar
  30. Heathcote, E.J., Shiffman, M.L., Cooksley, W.G., Dusheiko, G.M., Lee, S.S., Balart, L., Reindollar, R., Reddy, R.K., Wright, T.L., Lin, A., Hoffman, J., De Pamphilis, J. (2000). Peginterferon alpha-2a in patients with chronic hepatitis C and cirrhosis. New England Journal of Medicine, 343: 1673–1680.PubMedGoogle Scholar
  31. Hepburn, M.J., Hepburn, L.M., Cantu, N.S., Lapeer, M.G., Lawitz, E.J. (2004). Differences in treatment outcome for hepatitis C among ethnic groups. American Journal of Medicine, 117: 163–168.PubMedGoogle Scholar
  32. Hickman, I.J., Clouston, A.D., Macdonald, G.A., Purdie, D.M., Prins, J.B., Ash, S., Jonsson, J.R., Powell, E.E. (2002). Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut, 51: 89–94.PubMedGoogle Scholar
  33. Hickman, I.J., Powell, E.E., Prins, J.B., Clouston, A.D., Ash, S., Purdie, D.M., Jonsson, J.R. (2003). In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. Journal of Hepatology, 39: 1042–1048.PubMedGoogle Scholar
  34. Hoofnagle, J.H., Mullen, K.D., Jones, D.B., Rustgi, V., Di Bisceglie, A., Peters, M., Waggoner, J.G., Park, Y., Jones, E.A. (1986). Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. New England Journal of Medicine, 315: 1572–1578.Google Scholar
  35. Hung, C.H., Lee, C.M., Lu, S.N., Lee, J.F., Wang, J.H., Tung, H.D., Chen, T.M., Hu, T.H., Chen, W.J., Changchien, C.S. (2003). Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin. Journal of Viral Hepatitis, 10: 87–94.PubMedGoogle Scholar
  36. Hwang, Y., Chen, E.Y., Gu, Z.J., Chuang, W.L., Yu, M.L., Lai, M.Y., Chao, Y. ., Lee, C. ., Wang, J.H., Dai, C.Y., Shian-Jy Bey, M., Liao, Y.T., Chen, P.J., Chen, D.S. (2006). Genetic predisposition of responsiveness to therapy for chronic hepatitis C. Pharmacogenomics, 7: 697–709.PubMedGoogle Scholar
  37. International Interferon-Alpha Hepatocellular Carcinoma Study Group (1998). Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet, 351: 1535–1539.Google Scholar
  38. Jaeckel, E., Cornberg, M., Wedemeyer, H., Santantonio, T., Mayer, J., Zankel, M., Pastore, G., Dietrich, M., Trautwein, C., Manns, M.P. (2001). Treatment of acute hepatitis C with interferon alpha-2b. New England Journal of Medicine, 345: 1452–1457.PubMedGoogle Scholar
  39. Jensen, D.M., Morgan, T.R., Marcellin, P., Pockros, P.J., Reddy, K.R., Hadziyannis, S.J., Ferenci, P., Ackrill, A.M., Willems, B. (2006). Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology, 43: 954–960.PubMedGoogle Scholar
  40. Jian Wu, Y., Shu Chen, L., Gui Qiang, W. (2006). Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C. Liver International, 26: 166–172.PubMedGoogle Scholar
  41. Kamal, S.M., Fehr, J., Roesler, B., Peters, T., Rasenack, J.W. (2002). Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology, 123: 1070–1083.PubMedGoogle Scholar
  42. Kamal, S.M., Fouly, A.E., Kamel, R.R., Hockenjos, B., Al Tawil, A., Khalifa, K.E., He, Q., Koziel, M.J., El Naggar, K.M., Rasenack, J., Afdhal, N.H. (2006). Peginterferon alpha-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology, 130: 632–638.PubMedGoogle Scholar
  43. Kelleher, T. B., Afdhal, N. (2005). Maintenance therapy for chronic hepatitis C. Current Gastroenterology Reports, 7: 50–53.PubMedGoogle Scholar
  44. Kjaergard, L.L., Krogsgaard, K., Gluud, C. (2001). Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. British Medical Journal, 323: 1151–1155.PubMedGoogle Scholar
  45. Konishi, I., Horiike, N., Hiasa, Y., Michitaka, K., Onji, M. (2004). CCR5 promoter polymorphism influences the interferon response of patients with chronic hepatitis C in Japan. Intervirology, 47: 114–120.PubMedGoogle Scholar
  46. Lai, M.Y., Kao, J.H., Yang, P.M., Wang, J.T., Chen, P.J., Chan, K.W., Chu, J.S., Chen, D.S. (1996). Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology, 111: 1307–1312.PubMedGoogle Scholar
  47. Lau, D.T., Kleiner, D.E., Ghany, M.G., Park, Y., Schmid, P., Hoofnagle, J.H. (1998). 10-year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology, 28: 1121–1127.PubMedGoogle Scholar
  48. Lau, J.Y., Tam, R.C., Liang, T.J., Hong, Z. (2002). Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology, 35: 1002–1009.PubMedGoogle Scholar
  49. Layden, J.E., Layden, T.J. (2001). How can mathematics help us understand HCV? Gastroenterology, 120: 1546–1549.PubMedGoogle Scholar
  50. Lee, S.D., Yu, M.L., Cheng, P.N., Lai, M.Y., Chao, Y.C., Hwang, S.J., Chang, W.Y., Chang, T.T., Hsieh, T.Y., Liu, C.J., Chen, D.S. (2005). Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. Journal of Viral Hepatitis, 12: 283–291.PubMedGoogle Scholar
  51. Liaw, Y.F., Chen, Y.C., Sheen, I.S., Chien, R.N., Yeh, C.T., Chu, C.M. (2004). Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology, 126: 1024–1029.PubMedGoogle Scholar
  52. Lindahl, K., Stahle, L., Bruchfeld, A., Schvarcz, R. (2005). High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology, 41: 275–279.PubMedGoogle Scholar
  53. Lindsay, K.L., Trepo, C., Heintges, T., Shiffman, M.L., Gordon, S.C., Hoefs, J.C., Schiff, E.R., Goodman, Z.D., Laughlin, M., Yao, R., Albrecht, J.K. (2001). A randomized, double-blind trial comparing pegylated interferon alpha-2b to interferon alpha-2b as initial treatment for chronic hepatitis C. Hepatology, 34: 395–403.PubMedGoogle Scholar
  54. Liu, C.J., Chen, P.J., Lai, M.Y., Kao, J.H., Jeng, Y.M., Chen, D.S. (2003). Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology, 37: 568–576.PubMedGoogle Scholar
  55. Liu, C.J., Liou, J.M., Chen, D.S., Chen, P.J. (2005). Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections. Journal of the Formosan Medical Association, 104: 783–791.PubMedGoogle Scholar
  56. Mangia, A., Santoro, R., Minerva, N., Ricci, G.L., Carretta, V., Persico, M., Vinelli, F., Scotto, G., Bacca, D., Annese, M., Romano, M., Zechini, F., Sogari, F., Spirito, F., Andriulli, A. (2005). Peginterferon alpha-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. New England Journal of Medicine, 352: 2609–2617.PubMedGoogle Scholar
  57. Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V.K., Shiffman, M., Reindollar, R., Goodman, Z.D., Koury, K., Ling, M., Albrecht, J.K. (2001). Peginterferon alpha-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 358: 958–965.PubMedGoogle Scholar
  58. Marcellin, P., Boyer, N., Gervais, A., Martinot, M., Pouteau, M., Castelnau, C., Kilani, A., Areias, J., Auperin, A., Benhamou, J.P., Degott, C., Erlinger, S. (1997). Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Annals of Internal Medicine, 127: 875–881.PubMedGoogle Scholar
  59. Martinot-Peignoux, M., Marcellin, P., Pouteau, M., Castelnau, C., Boyer, N., Poliquin, M., Degott, C., Descombes, I., Le Breton, V., Milotova, V., et al. (1995). Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alpha therapy in chronic hepatitis C. Hepatology, 22: 1050–1056.PubMedGoogle Scholar
  60. McHutchison, J.G., Gordon, S.C., Schiff, E.R., Shiffman, M.L., Lee, W.M., Rustgi, V.K., Goodman, Z.D., Ling, M.H., Cort, S., Albrecht, J.K. (1998). Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. New England Journal of Medicine, 339: 1485–1492.PubMedGoogle Scholar
  61. McHutchison, J.G., Poynard, T. (1999). Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Seminars in Liver Disease, 19 Suppl. 1: 57–65.PubMedGoogle Scholar
  62. McHutchison, J.G., Poynard, T., Pianko, S., Gordon, S.C., Reid, A.E., Dienstag, J., Morgan, T., Yao, R., Albrecht, J. (2000). The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology, 119: 1317–1323.PubMedGoogle Scholar
  63. McHutchison, J.G., Manns, M., Patel, K., Poynard, T., Lindsay, K.L., Trepo, C., Dienstag, J., Lee, W.M., Mak, C., Garaud, J.J., Albrecht, J.K. (2002a). Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology, 123: 1061–1069.Google Scholar
  64. McHutchison, J.G., Poynard, T., Esteban-Mur, R., Davis, G.L., Goodman, Z.D., Harvey, J., Ling, M.H., Garaud, J.J., Albrecht, J.K., Patel, K., Dienstag, J.L., Morgan, T. (2002b). Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology, 35: 688–693.Google Scholar
  65. Moribe, T., Hayashi, N., Kanazawa, Y., Mita, E., Fusamoto, H., Negi, M., Kaneshige, T., Igimi, H., Kamada, T., Uchida, K. (1995). Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy. Gastroenterology, 108: 789–795.PubMedGoogle Scholar
  66. Muir, A.J., Bornstein, J.D., Killenberg, P.G. (2004). Peginterferon alpha-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. New England Journal of Medicine, 350: 2265–2271.PubMedGoogle Scholar
  67. National Institutes of Health Consensus Development Conference Panel (1997). Panel statement: management of hepatitis C. Hepatology, 26: 2S–10S.Google Scholar
  68. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002—June 10-12, 2002. Hepatology, 36: S3–20.Google Scholar
  69. Neumann, A.U., Lam, N.P., Dahari, H., Gretch, D.R., Wiley, T.E., Layden, T.J., Perelson, A.S. (1998). Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science, 282: 103–107.PubMedGoogle Scholar
  70. Neumann, A.U., Lam, N.P., Dahari, H., Davidian, M., Wiley, T.E., Mika, B.P., Perelson, A.S., Layden, T.J. (2000). Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. Journal of Infectious Disease, 182: 28–35.Google Scholar
  71. Niederau, C., Heintges, T., Haussinger, D. (1996). Treatment of chronic hepatitis C with a-interferon: an analysis of the literature. Hepatogastroenterology, 43: 1544–1556.PubMedGoogle Scholar
  72. Ohnishi, K., Matsuo, S., Matsutani, K., Itahashi, M., Kakihara, K., Suzuki, K., Ito, S., Fujiwara, K. (1996). Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. American Journal of Gastroenterology, 91: 1374–1379.PubMedGoogle Scholar
  73. Okada, S., Akahane, Y., Suzuki, H., Okamoto, H., Mishiro, S. (1992). The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology, 16: 619–624.PubMedGoogle Scholar
  74. Pascu, M., Martus, P., Hohne, M., Wiedenmann, B., Hopf, U., Schreier, E., Berg, T. (2004). Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut, 53: 1345–1351.PubMedGoogle Scholar
  75. Perez-Olmeda, M., Nunez, M., Romero, M., Gonzalez, J., Castro, A., Arribas, J.R., Pedreira, J., Barreiro, P., Garcia-Samaniego, J., Martin-Carbonero, L., Jimenez-Nacher, I., Soriano, V. (2003). Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS, 17: 1023–1028.PubMedGoogle Scholar
  76. Poynard, T., Leroy, V., Cohard, M., Thevenot, T., Mathurin, P., Opolon, P., Zarski, J.P. (1996). Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology, 24: 778–789.PubMedGoogle Scholar
  77. Poynard, T., Marcellin, P., Lee, S.S., Niederau, C., Minuk, G.S., Ideo, G., Bain, V., Heathcote, J., Zeuzem, S., Trepo, C., Albrecht, J. (1998). Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet, 352: 1426–1432.PubMedGoogle Scholar
  78. Poynard, T., McHutchison, J., Manns, M., Trepo, C., Lindsay, K., Goodman, Z., Ling, M.H., Albrecht, J. (2002). Impact of pegylated interferon alpha-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology, 122: 1303–1313.PubMedGoogle Scholar
  79. Reddy, K.R., Hoofnagle, J.H., Tong, M.J., Lee, W.M., Pockros, P., Heathcote, E.J., Albert, D., Joh, T. (1999). Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology, 30: 787–793.PubMedGoogle Scholar
  80. Reddy, K.R., Wright, T.L., Pockros, P.J., Shiffman, M., Everson, G., Reindollar, R., Fried, M.W., Purdum, P.P., 3rd, Jensen, D., Smith, C., Lee, W.M., Boyer, T.D., Lin, A., Pedder, S., DePamphilis, J. (2001). Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology, 33: 433–438.PubMedGoogle Scholar
  81. Reichard, O., Norkrans, G., Fryden, A., Braconier, J.H., Sonnerborg, A., Weiland, O. (1998). Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet, 351: 83–87.PubMedGoogle Scholar
  82. Romero-Gomez, M., Del Mar Viloria, M., Andrade, R.J., Salmeron, J., Diago, M., Fernandez-Rodriguez, C.M., Corpas, R., Cruz, M., Grande, L., Vazquez, L., Munoz-De-Rueda, P., Lopez-Serrano, P., Gila, A., Gutierrez, M.L., Perez, C., Ruiz-Extremera, A., Suarez, E., Castillo, J. (2005). Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology, 128: 636–641.PubMedGoogle Scholar
  83. Schalm, S.W., Hansen, B.E., Chemello, L., Bellobuono, A., Brouwer, J.T., Weiland, O., Cavalletto, L., Schvarcz, R., Ideo, G., Alberti, A. (1997). Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. Journal of Hepatology, 26: 961–966.PubMedGoogle Scholar
  84. Schalm, S.W., Weiland, O., Hansen, B.E., Milella, M., Lai, M.Y., Hollander, A., Michielsen, P.P., Bellobuono, A., Chemello, L., Pastore, G., Chen, D.S., Brouwer, J.T. (1999). Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis. Gastroenterology, 117: 408–413.PubMedGoogle Scholar
  85. Sen, G.C. (2001). Viruses and interferons. Annual Review of Microbiology, 55: 255–281.PubMedGoogle Scholar
  86. Sherman, M., Yoshida, E.M., Deschenes, M., Krajden, M., Bain, V.G., Peltekian, K., Anderson, F., Kaita, K., Simonyi, S., Balshaw, R., Lee, S.S. (2006). Peginterferon alpha-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut, 55: 1631–1638.PubMedGoogle Scholar
  87. Shiffman, M.L. (2002). Retreatment of patients with chronic hepatitis C. Hepatology, 36: S128–134.PubMedGoogle Scholar
  88. Shiffman, M.L. (2004). Retreatment of patients who do not respond to initial therapy for chronic hepatitis C. Cleveland Clinic Journal of Medicine, 71 Suppl. 3: S13–16.PubMedGoogle Scholar
  89. Shiffman, M.L., Di Bisceglie, A.M., Lindsay, K.L., Morishima, C., Wright, E.C., Everson, G.T., Lok, A.S., Morgan, T.R., Bonkovsky, H.L., Lee, W.M., Dienstag, J.L., Ghany, M.G., Goodman, Z.D., Everhart, J.E. (2004). Peginterferon alpha-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology, 126: 1015–1023.PubMedGoogle Scholar
  90. Shiratori, Y., Ito, Y., Yokosuka, O., Imazeki, F., Nakata, R., Tanaka, N., Arakawa, Y., Hashimoto, E., Hirota, K., Yoshida, H., Ohashi, Y., Omata, M. (2005). Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Annals of Internal Medicine, 142: 105–114.PubMedGoogle Scholar
  91. Strader, D.B., Wright, T., Thomas, D.L., Seeff, L.B. (2004). Diagnosis, management, and treatment of hepatitis C. Hepatology, 39: 1147–1171.PubMedGoogle Scholar
  92. Sugimoto, Y., Kuzushita, N., Takehara, T., Kanto, T., Tatsumi, T., Miyagi, T., Jinushi, M., Ohkawa, K., Horimoto, M., Kasahara, A., Hori, M., Sasaki, Y., Hayashi, N. (2002). A single nucleotide polymorphism of the low molecular mass polypeptide 7 gene influences the interferon response in patients with chronic hepatitis C. Journal of Viral Hepatitis, 9: 377–384.PubMedGoogle Scholar
  93. Suzuki, F., Arase, Y., Suzuki, Y., Tsubota, A., Akuta, N., Hosaka, T., Someya, T., Kobayashi, M., Saitoh, S., Ikeda, K., Kobayashi, M., Matsuda, M., Takagi, K., Satoh, J., Kumada, H. (2004). Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. Journal of Viral Hepatitis, 11: 271–276.PubMedGoogle Scholar
  94. Tabone, M., Sidoli, L., Laudi, C., Pellegrino, S., Rocca, G., Della Monica, P., Fracchia, M., Galatola, G., Molinaro, G.C., Arico, S., Pera, A. (2002). Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy. Journal of Viral Hepatitis, 9: 288–294.PubMedGoogle Scholar
  95. Tang, J., Kaslow, R.A. (2004). Pharmacogenomic perspectives of chronic hepatitis C virus (HCV) infection. Pharmacogenomics Journal, 4: 171–174.PubMedGoogle Scholar
  96. Thomas, D.L. (2002). Hepatitis C and human immunodeficiency virus infection. Hepatology, 36: S201–209.PubMedGoogle Scholar
  97. Thursz, M., Yallop, R., Goldin, R., Trepo, C., Thomas, H.C. (1999). Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet, 354: 2119–2124.PubMedGoogle Scholar
  98. Vidigal, P.G., Germer, J.J., Zein, N.N. (2002). Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. Journal of Hepatology, 36: 271–277.PubMedGoogle Scholar
  99. von Wagner, M., Huber, M., Berg, T., Hinrichsen, H., Rasenack, J., Heintges, T., Bergk, A., Bernsmeier, C., Haussinger, D., Herrmann, E., Zeuzem, S. (2005). Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology, 129: 522–527.Google Scholar
  100. Wiegand, J., Buggisch, P., Boecher, W., Zeuzem, S., Gelbmann, C.M., Berg, T., Kauffmann, W., Kallinowski, B., Cornberg, M., Jaeckel, E., Wedemeyer, H., Manns, M.P. (2006). Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology, 43: 250–256.PubMedGoogle Scholar
  101. Yee, L.J., Tang, J., Gibson, A.W., Kimberly, R., Van Leeuwen, D.J., Kaslow, R.A. (2001). Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology, 33: 708–712.PubMedGoogle Scholar
  102. Yee, L.J., Perez, K A., Tang, J., van Leeuwen, D.J., Kaslow, R.A. (2003). Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection. Journal of Infectious Disease, 187: 1264–1271.Google Scholar
  103. Yoshida, H., Shiratori, Y., Moriyama, M., Arakawa, Y., Ide, T., Sata, M., Inoue, O., Yano, M., Tanaka, M., Fujiyama, S., Nishiguchi, S., Kuroki, T., Imazeki, F., Yokosuka, O., Kinoyama, S., Yamada, G., Omata, M. (1999). Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Annals of Internal Medicine, 131: 174–181.PubMedGoogle Scholar
  104. Yoshida, H., Arakawa, Y., Sata, M., Nishiguchi, S., Yano, M., Fujiyama, S., Yamada, G., Yokosuka, O., Shiratori, Y., Omata, M. (2002). Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology, 123: 483–491.PubMedGoogle Scholar
  105. Yoshida, H., Tateishi, R., Arakawa, Y., Sata, M., Fujiyama, S., Nishiguchi, S., Ishibashi, H., Yamada, G., Yokosuka, O., Shiratori, Y., Omata, M. (2004). Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut, 53: 425–430.PubMedGoogle Scholar
  106. Yu, M.-L., Dai, C.-Y., Huang, J.-F., Hou, N.-J., Lee, L.-P., Hsieh, M.-Y., Chiu, C.-F., Lin, Z.-Y., Chen, S.-C., Hsieh, M.-Y., Wang, L.-Y., Chang, W.-Y., Chuang, W.-L. (2007). A randomised study of peginterferon and ribavirin for 16 vs 24 weeks in patients with genotype 2 chronic hepatitis C. Gut, 56: 553–559.PubMedGoogle Scholar
  107. Yu, M.L., Dai, C.Y., Chen, S.C., Chiu, C.C., Lee, L.P., Lin, Z.Y., Hsieh, M.Y., Wang, L.Y., Chuang, W.L., Chang, W.Y. (2003). Human leukocyte antigen class I and II alleles and response to interferon-alpha treatment, in Taiwanese patients with chronic hepatitis C virus infection. Journal of Infectious Disease, 188: 62–65.Google Scholar
  108. Yu, M.L., Dai, C.Y., Chiu, C.C., Lee, L.P., Lin, Z.Y., Chen, S.C., Hsieh, M.Y., Wang, L.Y., Chen, C.J., Chuang, W.L., Chang, W.Y. (2003). Tumor necrosis factor-alpha promoter polymorphisms at position -308 in Taiwanese chronic hepatitis C patients treated with interferon-alpha. Antiviral Research, 59: 35–40.PubMedGoogle Scholar
  109. Yu, M.L., Dai, C.Y., Chen, S.C., Lee, L.P., Huang, J.F., Lin, Z.Y., Hsieh, M.Y., Wang, L.Y., Chuang, W.L., Chang, W.Y. (2004). A prospective study on treatment of chronic hepatitis C with tailored and extended interferon-alpha regimens according to pretreatment virological factors. Antiviral Research, 63: 25–32.PubMedGoogle Scholar
  110. Yu, M.L., Dai, C.Y., Chen, S.C., Lee, L P., Hsieh, M.Y., Lin, Z.Y., Hsieh, M.Y., Wang, L.Y., Tsai, J.F., Chang, W.Y., Chuang, W.L. (2005). High versus standard doses interferon-alpha in the treatment of naive chronic hepatitis C patients in Taiwan: a 10-year cohort study. BMC Infectious Disease, 5: 27.Google Scholar
  111. Yu, M.L., Chuang, W.L., Dai, C.Y., Lee, L.P., Hsieh, M.Y., Lin, Z.Y., Chen, S.C., Hsieh, M.Y., Wang, L.Y., Chang, W.Y., Tsai, S.L., Kuo, H.T. (2006a). Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy. Translational Research, 148: 120–127.Google Scholar
  112. Yu, M.L., Dai, C.Y., Lin, Z.Y., Lee, L.P., Hou, N.J., Hsieh, M.Y., Chen, S.C., Hsieh, M.Y., Wang, L.Y., Chang, W.Y., Chuang, W.L. (2006b). A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan. Liver International, 26: 73–81.Google Scholar
  113. Yu, M.L., Lin, S.M., Chuang, W.L., Dai, C.Y., Wang, J.H., Lu, S.N., Sheen, I.S., Chang, W.Y., Lee, C.M., Liaw, Y.F. (2006c). A sustained virologic response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nation-wide, multicentre study in Taiwan. Antiviral Therapy, 11: 985–994.Google Scholar
  114. Zeuzem, S., Feinman, S.V., Rasenack, J., Heathcote, E.J., Lai, M.Y., Gane, E., O’Grady, J., Reichen, J., Diago, M., Lin, A., Hoffman, J., Brunda, M.J. (2000). Peginterferon alpha-2a in patients with chronic hepatitis C. New England Journal of Medicine, 343: 1666–1672.PubMedGoogle Scholar
  115. Zeuzem, S., Herrmann, E., Lee, J.H., Fricke, J., Neumann, A.U., Modi, M., Colucci, G., Roth, W.K. (2001). Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology, 120: 1438–1447.PubMedGoogle Scholar
  116. Zeuzem, S., Hultcrantz, R., Bourliere, M., Goeser, T., Marcellin, P., Sanchez-Tapias, J., Sarrazin, C., Harvey, J., Brass, C., Albrecht, J. (2004). Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. Journal of Hepatology, 40: 993–999.PubMedGoogle Scholar
  117. Zeuzem, S., Buti, M., Ferenci, P., Sperl, J., Horsmans, Y., Cianciara, J., Ibranyi, E., Weiland, O., Noviello, S., Brass, C., Albrecht, J. (2006). Efficacy of 24 weeks treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. Journal of Hepatology, 44: 97–103.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Ming-Lung Yu
    • 1
  • Wan-Long Chuang
  1. 1.Hepatobiliary Division,Department of Internal MedicineKaohsiung Medical University HospitalTaiwan

Personalised recommendations